Published in Scand J Infect Dis on March 01, 2010
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr (2007) 4.30
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr (2002) 3.55
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006) 2.61
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis (2004) 2.21
The extraordinary ligand binding properties of human serum albumin. IUBMB Life (2005) 2.00
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99
Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis (2008) 1.98
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother (2007) 1.89
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol (2005) 1.87
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2009) 1.81
Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar. Int J Infect Dis (2011) 1.78
Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev (2009) 1.76
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Med Genet (2014) 1.58
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis (2004) 1.55
Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses (2005) 1.52
Endobronchial ultrasound-driven biopsy in the diagnosis of peripheral lung lesions. Chest (2005) 1.51
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis (2003) 1.47
Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol (2002) 1.46
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol (2008) 1.45
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.41
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS (2005) 1.37
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 1.37
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35
Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses (2003) 1.29
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol (2006) 1.28
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother (2005) 1.23
Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.21
Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis (2010) 1.20
Leishmania infantum leishmaniasis in corticosteroid--treated patients. BMC Infect Dis (2006) 1.19
Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis (2010) 1.18
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr (2002) 1.14
Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. Hepatology (2014) 1.14
Primary human herpesvirus 8 infection in immunocompetent children. JAMA (2002) 1.13
Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis (2012) 1.12
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res (2009) 1.12
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother (2006) 1.11
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis (2012) 1.10
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol (2005) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis (2012) 1.09
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther (2004) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med (2003) 1.06
Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05
Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS (2005) 1.04
Varicella zoster virus infection presenting as isolated diplopia: a case report. BMC Infect Dis (2013) 1.04
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr (2012) 1.04
Use of massive parallel pyrosequencing for near full-length characterization of a unique HIV Type 1 BF recombinant associated with a fatal primary infection. AIDS Res Hum Retroviruses (2009) 1.04
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother (2010) 1.04
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr (2010) 1.03
Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. Infect Genet Evol (2005) 1.03
Eosinophilic meningitis in a returned traveler from Santo Domingo: case report and review. J Travel Med (2007) 1.02
Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis (2008) 1.01
Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr (2007) 1.01
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLoS One (2013) 1.00